Nucletron, BrachySolutions team for brachytherapy therapies

TriMed Staff | | Health Imaging | Oncology Imaging
Nucletron, a radiation oncology company, has formed a partnership with BrachySolutions, a breast brachytherapy company, to merge and co-market their high dose rate brachytherapy technologies.

Through the partnership, the companies said that radiation oncology centers in North America will have access to a team of brachytherapy experts available to assist centers in adapting brachytherapy technologies. Both companies also plan to leverage the deployment of Oncentra Brachy, a DICOM-compatible treatment planning solution for brachytherapy, recently launched by Nucletron.

“We believe that our partnership with BrachySolutions will enable our customers to accelerate their transition to 3D volumetric treatment planning and provide their patients with a complete set of APBI [accelerated partial breast irradiation] treatment options," said Bill Dowd, vice president of North America with Nucletron.”

The Columbia, Md.-based Nucletron and the Madison, Wis.-based BrachySolutions said they plan to initiate projects and joint marketing programs that incorporate the capabilities of both companies.

TriMed Staff

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.